All In Biotech

Drug Trial Radar · NCT06431373

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis

Last checked: Nov 19, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 371 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

371

Actual

Start

Sep 11, 2024

Primary completion

Sep 11, 2026

Study completion Feb 1, 2028

Sponsor

Lead sponsor
Priovant Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).

Conditions

  • Uveitis, Posterior
  • Uveitis, Intermediate
  • Uveitis

Interventions

  • Brepocitinib PO QDDrug

    Brepocitinib PO QD

  • Placebo PO QDDrug

    Placebo PO QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to treatment failure on or after Period 1 Week 6 up to Period 1 Week 48Time frame: 48 weeks

Locations

107 sites in 13 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Phoenix, Arizona

  • Clinical Trial Site

    Phoenix, Arizona

  • Clinical Trial Site

    Bakersfield, California

  • Clinical Trial Site

    Beverly Hills, California

  • Clinical Trial Site

    Fullerton, California

  • Clinical Trial Site

    Irvine, California

  • Clinical Trial Site

    La Jolla, California

  • Clinical Trial Site

    Los Angeles, California

  • Clinical Trial Site

    Los Angeles, California

  • Clinical Trial Site

    Modesto, California

  • Clinical Trial Site

    Sacramento, California

  • Clinical Trial Site

    Aurora, Colorado

  • Clinical Trial Site

    Denver, Colorado

  • Clinical Trial Site

    Fort Lauderdale, Florida

  • Clinical Trial Site

    St. Petersburg, Florida

  • Clinical Trial Site

    Chicago, Illinois

  • Clinical Trial Site

    Oak Park, Illinois

  • Clinical Trial Site

    Carmel, Indiana

  • Clinical Trial Site

    Prairie Village, Kansas

  • Clinical Trial Site

    Baltimore, Maryland

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    Waltham, Massachusetts

  • Clinical Trial Site

    Ann Arbor, Michigan

  • Clinical Trial Site

    Detroit, Michigan

  • Clinical Trial Site

    Detroit, Michigan

  • Clinical Trial Site

    Minneapolis, Minnesota

  • Clinical Trial Site

    Rochester, Minnesota

  • Clinical Trial Site

    St Louis, Missouri

  • Clinical Trial Site

    Omaha, Nebraska

  • Clinical Trial Site

    Palisades Park, New Jersey

  • NYU Langone Health

    New York, New York

  • Clinical Trial Site

    Rochester, New York

  • Clinical Trial Site

    Durham, North Carolina

  • Clinical Trial Site

    Winston-Salem, North Carolina

  • Clinical Trial Site

    Cleveland, Ohio

  • Clinical Trial Site

    Cleveland, Ohio

  • Clinical Trial Site

    Columbus, Ohio

  • Clinical Trial Site

    Portland, Oregon

  • Clinical Trial Site

    Portland, Oregon

  • Clinical Trial Site

    Erie, Pennsylvania

Showing 40 of 107 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.